PUMA BIOTECHNOLOGY, INC.

PBYI ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item Jun 2020 Mar 2020 Dec 2019 Sep 2019 Jun 2019 Mar 2019 Dec 2018 Sep 2018
Operating Activities
Net Income $3.4M $-16.9M $-11.2M $-16.9M $-37.4M $-10.1M $-30.7M $-14.2M
Depreciation & Amortization $2.2M $1.9M $1.9M $1.9M $2.1M $2.1M $2.1M $2.1M
Depreciation $300.0K $200.0K $200.0K $200.0K
Amortization $1.3M $1.0M $900.0K $1.0M $1.0M $1.0M $900.0K $1.0M
Stock-Based Compensation $10.6M $8.9M $11.5M $12.2M $15.4M $18.1M $18.6M $20.8M
Net Cash from Operating Activities $16.2M $-11.5M $1.6M $-7.3M $44.2M $-16.1M $7.0M $-7.3M
Investing Activities
Capital Expenditures $-111.0K $305.0K
Business Acquisitions
Net Cash from Investing Activities $-9.2M $34.4M $-432.0K $39.0M $11.2M $-44.6M $2.6M $-21.4M
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $-1.0K $76.0K $-68.2M $1.1M $30.5M $1.0M
Net Change in Cash $7.0M $22.8M $1.1M $31.7M $-12.8M $-59.6M $40.1M $-27.6M
Free Cash Flow $7.2M $-7.6M
← Newer Page 4 of 8 Older →